MNG571
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.314
- BILE_ACID_METABOLISM+0.246
- P53_PATHWAY+0.221
- PEROXISOME+0.214
- MYC_TARGETS_V2+0.198
- XENOBIOTIC_METABOLISM+0.193
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.181
- DNA_REPAIR+0.172
- APOPTOSIS+0.150
- FATTY_ACID_METABOLISM+0.133
Top 10 suppressed
- E2F_TARGETS-0.376
- PROTEIN_SECRETION-0.365
- UV_RESPONSE_DN-0.358
- ANGIOGENESIS-0.352
- G2M_CHECKPOINT-0.330
- MTORC1_SIGNALING-0.327
- ANDROGEN_RESPONSE-0.269
- INTERFERON_ALPHA_RESPONSE-0.266
- KRAS_SIGNALING_UP-0.234
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.221
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001524_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.787 |
| 2 | MNG559 | — | — | 0.767 |
| 3 | MNG1240 | — | — | 0.761 |
| 4 | MNG411 | — | — | 0.756 |
| 5 | R215 | — | — | 0.752 |
| 6 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.745 |
| 7 | SRR23303730 | — | — | 0.730 |
| 8 | SRR12475123 | — | — | 0.713 |
| 9 | MNG656 | — | — | 0.711 |
| 10 | c2e34dda-0852-492e-9cde-3ff606259c12 | — | — | 0.710 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.314 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.246 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.221 | Idelalisib | — uncovered |
| PEROXISOME | 0.214 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.198 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.193 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.181 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.172 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.133 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.119 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.103 | Idelalisib | — uncovered |
| COAGULATION | 0.077 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.038 | Inavolisib | — uncovered |
| MYOGENESIS | 0.009 | Inavolisib | — uncovered |